顺铂培美曲塞对老年晚期非鳞状非小细胞肺癌的疗效评价

目的探讨顺铂一线联合培美曲塞对老年晚期非鳞状非小细胞肺癌临床疗效。方法对我院收治的122例患者随机分为实验组以及对照组,对照组采用顺铂一线进行治疗,实验组采用顺铂一线联合培美曲塞进行治疗,对两组患者治疗疗效以及毒副反应进行比较。结果实验组治疗有效率为27.87%,控制率为78.69%,而对照组分别为8.20%以及39.34%。实验组患者TTP为166±13 d,中位生存时间为287 d。对照组TTP为104±12 d,中位生存时间为174 d,两组患者在中位生存时间以及TTP比较中有明显的差异性;实验组患者发生不良反应率明显低于对照组。结论对老年晚期非鳞状非小细胞肺癌采用顺铂一线联合培美曲塞进行治疗,可有效改善预后,提高患者生存质量。

Evaluation of the effect of cisplatin combined with pemetrexed as the first-line treatment of elderly patients with advanced non-squamous non-small cell lung cancer

Objective To evalute the efficacy of cisplatin combined with pemetrexed as the first-line treatment of elderly patients with advanced non-squamous non-small cell lung cancer. Methods 122 patients were randomly divided into the experimental group and the control group. The control group were given the first-line cisplatin treatment, while the experimental group were treated with cisplatin combined with pemetrexed. The treatment efficacy as well as the adverse reaction was compared between the two groups. Results In the experimental group, the effective rate of 27. 87%, the control rate was 78.69%, while the effective rate and control rate in the control group was 8.20% and 39. 34% respectively. The TTP was 166 ± 13d and the median survival time was 287d in the experimental group, while 104± 12d and 174d in the control group respectively. There were significant differences in median survival time and ＇I＇FP between the two groups of patients. The incidence of adverse reactions occurred was significantly lower in the experimental group than in the control group. Conclusion Cisplatin combined with pemetrexed can effectively improve the prognosis and quality of life as the first-line treatment of elderly patients with advanced non-squamous non-small cell lung cancer.